Tasquinimod-d_3

Cat. No.:	HY-10528S
CAS No.:	1416701-99-9
Molecular Formula:	$C_{20}H_{14}D_3F_3N_2O_4$
Molecular Weight:	409.37
Target:	HDAC; Isotope-Labeled Compounds
Pathway:	Cell Cycle/DNA Damage; Epigenetics; Others
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (244.28 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	2.4428 mL	12.2139 mL	24.4278 mL
	5 mM	0.4886 mL	2.4428 mL	4.8856 mL
	10 mM	0.2443 mL	1.2214 mL	2.4428 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Tasquinimod-d3 (ABR-215050-d3) is the deuterium labeled Tasquinimod (HY-10528). Tasquinimod is an oral antiangiogenic agent, which plays an important role in castration-resistant prostate cancer. Tasquinimod binds to the regulatory Zn^{2+} binding domain of HDAC4 with K_d of 10-30 nM. Tasquinimod also is a S100A9 inhibitor[1][2][3].

REFERENCES

[1]. Isaacs JT, et al. Tasquinimod Is an Allosteric Modulator of HDAC4 survival signaling within the compromised cancer microenvironment. Cancer Res. 2013 Feb 15;73(4):1386-99.

[2]. Olsson A, et al. Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors. Mol Cancer. 2010 May 17;9:107.

[3]. Isaacs JT, et al. Anti-cancer potency of tasquinimod is enhanced via albumin-binding facilitating increased uptake in the tumor microenvironment. Oncotarget. 2014 Sep 30;5(18):8093-106.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA